Renalytix Eyes Revenue Growth as Kidney Diagnostic Expands U.S. Footprint

The latest announcement is out from Renalytix ( (GB:RENX) ).

Renalytix reported unaudited first-half fiscal 2026 revenues of $1.6 million and forecast full-year revenue of about $4 million, a 33% increase year-on-year, as it accelerates electronic medical record integrations for its kidneyintelX.dkd test across U.S. healthcare providers. The company is planning a large-scale integration with a major regional health system, expanding access to potentially more than 40,000 chronic kidney disease patients, while relocating its lab to cut operating costs, advancing a real-world evidence study and Tempus AI collaboration, and preparing new clinical data aimed at driving broader clinical adoption and payer coverage.

The most recent analyst rating on (GB:RENX) stock is a Sell with a £5.00 price target. To see the full list of analyst forecasts on Renalytix stock, see the GB:RENX Stock Forecast page.

Spark’s Take on GB:RENX Stock

According to Spark, TipRanks’ AI Analyst, GB:RENX is a Neutral.

The score is held down primarily by weak financial performance (large losses, negative equity, and ongoing cash burn) and a bearish technical trend (price below key moving averages and negative MACD). Positive corporate updates and oversold signals provide some support, but they do not offset current financial and trend risk.

To see Spark’s full report on GB:RENX stock, click here.

More about Renalytix

Renalytix is a London- and New York-based artificial intelligence-enabled in vitro diagnostics company focused on improving clinical management of kidney disease. Its flagship product, kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in chronic diabetic kidney disease and is being deployed across major U.S. healthcare systems.

Average Trading Volume: 497,512

Technical Sentiment Signal: Sell

Current Market Cap: £25.35M

See more data about RENX stock on TipRanks’ Stock Analysis page.